JP2010506918A - ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター - Google Patents
ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター Download PDFInfo
- Publication number
- JP2010506918A JP2010506918A JP2009533349A JP2009533349A JP2010506918A JP 2010506918 A JP2010506918 A JP 2010506918A JP 2009533349 A JP2009533349 A JP 2009533349A JP 2009533349 A JP2009533349 A JP 2009533349A JP 2010506918 A JP2010506918 A JP 2010506918A
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- methyl
- group
- biphenyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KWKFNOKDAQRAET-LJQANCHMSA-N CC(C)CS(c(cc1)ccc1-c1ccc(CCN2[C@H](C)CCC2)cc1)(=O)=O Chemical compound CC(C)CS(c(cc1)ccc1-c1ccc(CCN2[C@H](C)CCC2)cc1)(=O)=O KWKFNOKDAQRAET-LJQANCHMSA-N 0.000 description 1
- YTYRGZBOJGXYBV-UHFFFAOYSA-N COCS(c(cc1)ccc1Br)(=O)=O Chemical compound COCS(c(cc1)ccc1Br)(=O)=O YTYRGZBOJGXYBV-UHFFFAOYSA-N 0.000 description 1
- ZBXYAAXRAYLIRE-UHFFFAOYSA-N COCSc(cc1)ccc1Br Chemical compound COCSc(cc1)ccc1Br ZBXYAAXRAYLIRE-UHFFFAOYSA-N 0.000 description 1
- AZEZHOPXSWLOJK-JOCHJYFZSA-N C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(CCNC2CCCCC2)(=O)=O)CCC1 Chemical compound C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(CCNC2CCCCC2)(=O)=O)CCC1 AZEZHOPXSWLOJK-JOCHJYFZSA-N 0.000 description 1
- LKSOUSYVEIFFAF-QGZVFWFLSA-N C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(CCO)(=O)=O)CCC1 Chemical compound C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(CCO)(=O)=O)CCC1 LKSOUSYVEIFFAF-QGZVFWFLSA-N 0.000 description 1
- BPPADGBWXFDIBT-QGZVFWFLSA-N C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(COC)(=O)=O)CCC1 Chemical compound C[C@H]1N(CCc(cc2)ccc2-c(cc2)ccc2S(COC)(=O)=O)CCC1 BPPADGBWXFDIBT-QGZVFWFLSA-N 0.000 description 1
- AJLVABJJAOXSCI-CQSZACIVSA-N C[C@H]1N(CCc(cc2)ccc2-c(cn2)cnc2S(C)(=O)=O)CCC1 Chemical compound C[C@H]1N(CCc(cc2)ccc2-c(cn2)cnc2S(C)(=O)=O)CCC1 AJLVABJJAOXSCI-CQSZACIVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85261006P | 2006-10-17 | 2006-10-17 | |
| US93435807P | 2007-06-11 | 2007-06-11 | |
| PCT/US2007/022086 WO2008048609A1 (en) | 2006-10-17 | 2007-10-16 | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010506918A true JP2010506918A (ja) | 2010-03-04 |
| JP2010506918A5 JP2010506918A5 (enExample) | 2010-11-25 |
Family
ID=39149258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533349A Withdrawn JP2010506918A (ja) | 2006-10-17 | 2007-10-16 | ヒスタミンｈ３受容体に関連する障害の処置に有用なヒスタミンｈ３受容体のビフェニルスルホニルおよびフェニル−ヘテロアリールスルホニルモジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100240653A1 (enExample) |
| EP (1) | EP2074086B1 (enExample) |
| JP (1) | JP2010506918A (enExample) |
| KR (1) | KR20090069333A (enExample) |
| AR (1) | AR063226A1 (enExample) |
| AT (1) | ATE512948T1 (enExample) |
| AU (1) | AU2007313180A1 (enExample) |
| CA (1) | CA2665204A1 (enExample) |
| CL (1) | CL2007002977A1 (enExample) |
| EA (1) | EA200970386A1 (enExample) |
| IL (1) | IL197892A0 (enExample) |
| MX (1) | MX2009004071A (enExample) |
| PA (1) | PA8750901A1 (enExample) |
| PE (1) | PE20081462A1 (enExample) |
| TW (1) | TW200823204A (enExample) |
| WO (1) | WO2008048609A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012232978A (ja) * | 2011-05-02 | 2012-11-29 | Lab Servier | ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物 |
| JP2016504388A (ja) * | 2013-01-09 | 2016-02-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 認識障害の処置のためのヒスタミンｈ３受容体調節因子としてのビフェニル−エチル−ピロリジン誘導体 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ544331A (en) | 2003-07-22 | 2010-03-26 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
| WO2009123714A2 (en) * | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| JP2011518154A (ja) * | 2008-04-16 | 2011-06-23 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−１−｛２−［４’−（３−メトキシプロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの合成に有用なプロセス |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| TR201805216T4 (en) | 2008-10-28 | 2018-06-21 | Arena Pharm Inc | COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS |
| GB201005511D0 (en) | 2010-03-31 | 2010-05-19 | Takeda Pharmaceutical | Compounds and their use |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| CN108472285A (zh) | 2015-07-15 | 2018-08-31 | 阿速万科学有限责任公司 | 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物 |
| WO2020092604A1 (en) * | 2018-10-30 | 2020-05-07 | Concert Pharmaceuticals, Inc. | Deuterated pitolisant |
| EP4251148A1 (en) | 2020-11-27 | 2023-10-04 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
| CN115160584B (zh) * | 2022-07-06 | 2024-03-22 | 西北工业大学 | 一种基于阳离子-π与静电作用协同构筑异质孔超分子有机框架及制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352707A (en) * | 1992-03-26 | 1994-10-04 | Harbor Branch Oceanographic Institution, Inc. | Method for treating airway congestion |
| US5217986A (en) * | 1992-03-26 | 1993-06-08 | Harbor Branch Oceanographic Institution, Inc. | Anti-allergy agent |
| DE69333489T2 (de) * | 1992-09-14 | 2005-04-14 | Takeda Chemical Industries, Ltd. | Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten |
| US5541217A (en) * | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
| US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
| US20040044029A1 (en) * | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| US7244852B2 (en) * | 2003-02-27 | 2007-07-17 | Abbott Laboratories | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof |
| GB0308333D0 (en) * | 2003-04-10 | 2003-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2561628C (en) * | 2004-04-01 | 2012-05-08 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
| US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
| US7145005B2 (en) * | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| CA2579204A1 (en) * | 2004-09-07 | 2006-03-16 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| MX2007006387A (es) * | 2004-12-03 | 2007-06-20 | Hoffmann La Roche | Derivados de piridina 3-substituidos como antagonistas h3. |
| AU2006207712A1 (en) * | 2005-01-19 | 2006-07-27 | F. Hoffmann-La Roche Ag | 5-aminoindole derivatives |
| US20060188960A1 (en) * | 2005-02-18 | 2006-08-24 | Waters Stephen M | Chimeric histamine H3 receptor |
| AU2006261162A1 (en) * | 2005-06-17 | 2006-12-28 | Janssen Pharmaceutica N.V. | Naphthyridine compounds |
| KR101336106B1 (ko) * | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| DE602006020482D1 (de) * | 2005-11-30 | 2011-04-14 | Hoffmann La Roche | 1,5-substituierte indol-2-yl amidderivative |
| AU2006331850A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine H3 antagonists |
| WO2007108936A2 (en) * | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| CA2649913A1 (en) * | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| MX339668B (es) * | 2006-05-30 | 2016-06-02 | Janssen Pharmaceutica N V * | Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina. |
| EP2035372A1 (en) * | 2006-06-29 | 2009-03-18 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| US7648979B2 (en) * | 2007-02-07 | 2010-01-19 | Hoffmann-La Roche Inc. | 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives |
| US7557108B2 (en) * | 2007-02-07 | 2009-07-07 | Hoffmann-La Roche Inc. | (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones |
| US7507736B2 (en) * | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
| WO2008144305A1 (en) * | 2007-05-18 | 2008-11-27 | Janssen Pharmaceutica N.V. | Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators |
| AR066721A1 (es) * | 2007-05-24 | 2009-09-09 | Wyeth Corp | Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso. |
| US20090069300A1 (en) * | 2007-09-12 | 2009-03-12 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| WO2009067406A1 (en) * | 2007-11-20 | 2009-05-28 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
-
2007
- 2007-09-28 TW TW096136478A patent/TW200823204A/zh unknown
- 2007-10-10 AR ARP070104474A patent/AR063226A1/es not_active Application Discontinuation
- 2007-10-16 EP EP07852791A patent/EP2074086B1/en active Active
- 2007-10-16 KR KR1020097009992A patent/KR20090069333A/ko not_active Withdrawn
- 2007-10-16 WO PCT/US2007/022086 patent/WO2008048609A1/en not_active Ceased
- 2007-10-16 CA CA002665204A patent/CA2665204A1/en not_active Abandoned
- 2007-10-16 EA EA200970386A patent/EA200970386A1/ru unknown
- 2007-10-16 US US12/445,795 patent/US20100240653A1/en not_active Abandoned
- 2007-10-16 MX MX2009004071A patent/MX2009004071A/es active IP Right Grant
- 2007-10-16 AU AU2007313180A patent/AU2007313180A1/en not_active Abandoned
- 2007-10-16 PE PE2007001398A patent/PE20081462A1/es not_active Application Discontinuation
- 2007-10-16 JP JP2009533349A patent/JP2010506918A/ja not_active Withdrawn
- 2007-10-16 AT AT07852791T patent/ATE512948T1/de not_active IP Right Cessation
- 2007-10-17 PA PA20078750901A patent/PA8750901A1/es unknown
- 2007-10-17 CL CL200702977A patent/CL2007002977A1/es unknown
-
2009
- 2009-04-05 IL IL197892A patent/IL197892A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012232978A (ja) * | 2011-05-02 | 2012-11-29 | Lab Servier | ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物 |
| JP2016504388A (ja) * | 2013-01-09 | 2016-02-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 認識障害の処置のためのヒスタミンｈ３受容体調節因子としてのビフェニル−エチル−ピロリジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE512948T1 (de) | 2011-07-15 |
| AU2007313180A1 (en) | 2008-04-24 |
| PE20081462A1 (es) | 2008-10-18 |
| KR20090069333A (ko) | 2009-06-30 |
| PA8750901A1 (es) | 2009-03-31 |
| CA2665204A1 (en) | 2008-04-24 |
| EP2074086A1 (en) | 2009-07-01 |
| CL2007002977A1 (es) | 2008-06-06 |
| AR063226A1 (es) | 2009-01-14 |
| MX2009004071A (es) | 2009-04-28 |
| EA200970386A1 (ru) | 2009-10-30 |
| WO2008048609A1 (en) | 2008-04-24 |
| EP2074086B1 (en) | 2011-06-15 |
| IL197892A0 (en) | 2009-12-24 |
| US20100240653A1 (en) | 2010-09-23 |
| TW200823204A (en) | 2008-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2074086B1 (en) | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto | |
| JP2009542673A (ja) | ヒスタミンｈ３−受容体関連障害の治療に有用なヒスタミンｈ３−受容体モジュレータ | |
| WO2007088450A2 (en) | Chromane antagonist of the h-3 receptor | |
| JP2005255685A (ja) | カンナビノイド受容体に作用する新規なピラゾール類似体 | |
| JP2008526887A (ja) | カンナビノイド受容体に作用する新規なヘテロピロール類似体 | |
| AU2008319310A1 (en) | Biphenyl derivatives as modulators of the histamine-H3 receptor useful for the treatment of disorders related thereto | |
| US20100331312A1 (en) | Modulators of the histamine h3 receptor useful for the treatment of disorders related thereto | |
| US20100292288A1 (en) | Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| CN101821247A (zh) | 作为hsp90抑制剂的抗癌用5-(2-羟基苯基)四唑化合物 | |
| EP2943473B1 (en) | Biphenyl-ethyl-pyrrolidine derivatives as histamine h3 receptor modulators for the treatment of cognitive disorders | |
| EP1948605A2 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| CN101528684A (zh) | 适用于治疗组胺h3受体相关病症的组胺h3受体的联苯磺酰基和苯基-杂芳基磺酰基调节剂 | |
| JP3786984B2 (ja) | ピペラジン誘導体 | |
| HK1253019B (en) | (r)-3-(4'-(2-(2-methylpyrrolidin-1-yl)ethyl)biphenyl-4-yl)propanoic acid as histamine h3 receptor modulators for the treatment of cognitive disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101008 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20120209 |
|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20120306 |